

## Article with exploratory alkylator-refractory subgroup analysis from Oncopeptides' OCEAN study observing longer PFS and OS in melflufen vs. pomalidomide published in European Journal of Haematology

Stockholm – November 17, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, has been published in the European Journal of Haematology, an international journal for communication of research in hematology. The results further demonstrate efficacy and consistent safety profile in patients with alkylator-refractory disease.

The article, “Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: a subgroup analysis from the OCEAN study” describes a post-hoc exploratory analysis where 153 patients refractory from prior alkylators in the OCEAN study were evaluated. Among the findings, the study shows that the observed median progression free survival, PFS, and overall survival, OS, were longer in the melflufen arm than in the comparator arm in patients that had either no prior autologous stem cell transplant (ASCT) or a progression-free period after ASCT of at least 36 months. The results suggest that melflufen is safe and effective in patients with alkylator-refractory disease, suggesting differentiated activity from other alkylators.

The full article can be [found here](#).

The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.

“This article is yet another example of how the OCEAN study documents that melflufen is well positioned to addresses the high unmet medical need among elderly patients suffering from relapsed refractory multiple myeloma,” says Stefan Norin, Chief Medical Officer at Oncopeptides. “We will continue to work diligently to further communicate to the medical community the added efficacy, safety and quality of life that melflufen brings to patients.”

For more information, please visit [our website](#), where you can also find a Q&A for investors.

### For more information, please contact:

David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)

E-mail: [david.augustsson@oncopeptides.com](mailto:david.augustsson@oncopeptides.com)

Cell phone: +46 76 229 38 68

## About Oncopeptides

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: [www.oncopeptides.com](http://www.oncopeptides.com).

## Attachments

[Article with exploratory alkylator-refractory subgroup analysis from Oncopeptides' OCEAN study observing longer PFS and OS in melflufen vs. pomalidomide published in European Journal of Haematology](#)